<p style = "font-size:20px">PMC6217729</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC6217729#opentargets-dc7ebc8b22a62a77d3398b01637f2ec6"> CXCL12 in the TME may recruit CXCR4-expressing immunosuppressive cells such as tumor-associated macrophages (TAM), myeloid-derived suppressor cells (MDSC), <font color="#b49700">cancer</font>-associated fibroblasts (<font color="red">CAF</font>), and regulatory T cells (Treg) to the tumor niche.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC6217729#opentargets-0f82473438e5acec3a1298c7805e50d6"> Ibrutinib, a Bruton's tyrosine kinase inhibitor, was shown to down-regulate PD-L1 expression on <font color="#b49700">tumor</font> cells and PD1 in <font color="red">CD4</font>+ and CD8+ T cells via inhibition of STAT3 and also decreased IL-10 production by chronic lymphocytic leukemia (CLL) cells in patients (69).</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC6217729#opentargets-1d68d0179407a5f18c1645385f4eb56c"> <font color="red">ECM</font> remodeling may be important for <font color="#b49700">tumor</font> invasion and metastasis.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC6217729#opentargets-91528496f7365fdad796eda54b2b7115"> Decreased Treg infiltration in <font color="#b49700">tumors</font> showed that AMD3100 lowered PD1 expression on CD8+ T cells and converted Tregs into helper-like cells (CD4+CD25−Foxp3+<font color="red">IL2</font>+CD40L+).</a></p><p style = "font-size:20px">PMC6199385</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC6199385#opentargets-437e374c80c9f473d4872a8ffa9402f8">CART and solid malignanciesCARs have also been developed against a variety of solid <font color="#b49700">tumor</font> surface antigens including mesothelin (31), carcinoembryonic antigen (<font color="red">CEA</font>) (32), disialoganglioside (GD2) (33), interleukin-13 receptor α2 (IL-13Rα2) (34), mucin-1 (MUC1) (35, 36), ephrin type-A receptor 2 (EphA2), (37), human epidermal growth factor receptor 2 (HER2) (38) and other growth factor receptors.</a></p><p style = "font-size:20px">PMC6207735</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC6207735#opentargets-535a100c50cb7ad031d33aa010ec96e2"> These observations indicate that the progression of <font color="#b49700">cancer</font> cells through the expression of <font color="red">ERα</font> was enhanced due to the loss of transcriptional suppression caused by the cytoplasmic localization of the SIN3A p.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC6207735#opentargets-e1105f5419f1e08b269a9c14b142a741"> In a recent report, likely driver mutations were newly identified in the exon regions of AKT2, ARID1B, CASP8, CDKN1B, MAP3K1, MAP3K13, NCOR1, SMRCD1, and TBX3 based on analyses of the coding exon regions in 100 primary <font color="#b49700">breast cancers</font> in addition to the mutations previously identified in AKT1, BRCA1, CDH1, GATA3, PIK3CA, PTEN, <font color="red">RB1</font>, and TP5313.</a></p><p style = "font-size:20px">PMC6181399</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/30308041#opentargets-7a098765d545f341f9486f70fe684162"> Based on these findings we performed detailed studies of the B-cell specific <font color="red">NKL</font> homeobox gene NKX6-3 which showed enhanced activity in patient subsets of follicular lymphoma, <font color="#b49700">mantle cell lymphoma</font> and diffuse large B-cell lymphoma (DLBCL), and in three DLBCL cell lines to serve as in vitro models.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC6181399#opentargets-e5a25566861a99bbce1aedad5e29252f">Aberrant activities of NKL homeobox genes are reported in B-cell malignancies as well, comprising <font color="red">HLX</font> in Hodgkin lymphoma (HL), MSX1 in mantle cell lymphoma (MCL), NKX2-1 in diffuse large B-cell lymphoma (<font color="#b49700">DLBCL</font>), and NKX2-3 in splenic marginal zone lymphoma (SMZL), mucosa-associated lymphoid tissue (MALT) lymphoma, and <font color="#b49700">DLBCL</font> [22–25].</a></p><p style = "font-size:20px">PMC6174070</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC6174070#opentargets-4cba09f0788e57873c139d901ac80621"> QRT-PCR analyses of pro-inflammatory factor gene expression (IL-1β, IL-6, IL-8, <font color="red">OSM</font>, and TNFα) in neutrophils (g).Transwell migration assays for <font color="#b49700">gastric cancer</font> cells following treatment with supernatant from neutrophils (h).</a></p><p style = "font-size:20px">PMC6166462</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC6166462#opentargets-da930ef5b78db50075176e42be64af85">Abnormal activation of the PI3K/<font color="red">Akt</font> pathway is closely related to <font color="#b49700">tumor</font> development; activated PI3K converts PIP2 to PIP3, which acts as a second messenger to activate a number of signaling molecules downstream of the signal pathway involved in cell proliferation, differentiation, apoptosis, survival, and migration.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC6166462#opentargets-9565109670a5ef29b658163bf2bbfc9f">TRAIL is a member of the <font color="red">TNF</font> superfamily that can induce <font color="#b49700">tumor</font> cell apoptosis through binding with its receptor.</a></p><p style = "font-size:20px">PMC6143188</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/30226896#opentargets-4e77cef8c8631537db8d0a499b3a4630"> Furthermore, CD43-/-septic mice exhibited a prominent Th2 skewing following <font color="#b49700">sepsis</font> relative to WT septic mice, as evidenced by a significant decrease in the frequency of IL-2+ CXCR3+ <font color="red">TH1</font> cells as a significant increase in the frequency of IL-4+ CCR4+ TH2 cells.</a></p><p style = "font-size:20px">PMC6135697</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/30220970#opentargets-11bd5c6424e037577af8e4b42ac01a3c"> Using this technology, we quantitatively measured the expression levels of 10 proteins: alpha-fetoprotein (AFP), beta 2 microglobulin (B2M), <font color="#b49700">Carcinoma</font> Antigen 15-3(CA15-3), Carcinoembryonic antigen (CEA), golgi protein 73 (GP73), Growth differentiation factor 15 (GDF15), Human Epididymis Protein 4 (<font color="red">HE4</font>), Insulin Like Growth Factor Binding Protein 2 (IGFBP2), osteopontin (OPN) and Beta-type platelet-derived growth factor receptor (PDGFRB) from serum samples of 132 hepatocellular carcinoma (HCC) patients and 78 healthy volunteers.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/30220970#opentargets-8b2c08d48d48dd8a1ff677c4283ef1ea"> Using this technology, we quantitatively measured the expression levels of 10 proteins: alpha-fetoprotein (AFP), beta 2 microglobulin (<font color="red">B2M</font>), <font color="#b49700">Carcinoma</font> Antigen 15-3(CA15-3), Carcinoembryonic antigen (CEA), golgi protein 73 (GP73), Growth differentiation factor 15 (GDF15), Human Epididymis Protein 4 (HE4), Insulin Like Growth Factor Binding Protein 2 (IGFBP2), osteopontin (OPN) and Beta-type platelet-derived growth factor receptor (PDGFRB) from serum samples of 132 hepatocellular carcinoma (HCC) patients and 78 healthy volunteers.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/30220970#opentargets-951b870e170c279f0c30a1eaa2a865b3"> Using this technology, we quantitatively measured the expression levels of 10 proteins: alpha-fetoprotein (AFP), beta 2 microglobulin (B2M), <font color="#b49700">Carcinoma</font> Antigen 15-3(CA15-3), Carcinoembryonic antigen (CEA), golgi protein 73 (GP73), Growth differentiation factor 15 (GDF15), Human Epididymis Protein 4 (HE4), Insulin Like Growth Factor Binding Protein 2 (IGFBP2), osteopontin (<font color="red">OPN</font>) and Beta-type platelet-derived growth factor receptor (PDGFRB) from serum samples of 132 hepatocellular carcinoma (HCC) patients and 78 healthy volunteers.</a></p><p style = "font-size:20px">PMC6125410</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/30185896#opentargets-bc87e17c3b4a5abc8a6de1e0e073279c"> TiHo-0906 CNVs affect several genomic regions harbouring known EMT-, <font color="#b49700">breast cancer</font>-, and hMBCs-associated genes as AKT1, GATA3, CCND2, CDK4, ZEB1, KRAS, HMGA2, ESRP1, MTDH, YWHAZ, and <font color="red">MYC</font>.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC6125410#opentargets-34d9a85b4216dae51f4205413fe4dac6"> Additionally, TiHo-0906 cells at low and high passage also displayed CNGs in regions harbouring other known <font color="#b49700">breast cancer</font>-related genes like FOXO3 and <font color="red">MYB</font> (FCA B2), AKT1 (FCA B3), and GATA-3, CCND2, CDK4 and PFDN5 (FCA B4).</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC6125410#opentargets-6021e0b925c3e8dfda3e17b0b4ac9f4d"> Additional CNLs affecting known <font color="#b49700">breast cancer</font>-, hMBCs-, and EMT-related genes were only detected after prolonged subculturing; including, FCA A1 containing TERT, BRCA2, RB1, and FOXO1 genes; chromosome A2 harbouring EGFR, TWIST, MLL2, and AHR; chromosomes B2, B3, and B4 harbouring CCND3, FOXA1, and MDM2, respectively; and chromosome E1 harbouring <font color="red">NF1</font>, PPM1D, and KSR1.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC6125410#opentargets-5a9eb82ab0a68a0a8dec7266c894a46a"> In general, a co-expression of epithelial markers and <font color="red">Vim</font> was observed in tubular and solid anaplastic areas of the <font color="#b49700">tumour</font>.</a></p><p style = "font-size:20px">PMC6090877</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/30131766#opentargets-63494bb9d1f82633a843e950de3dbd99">00423EndocrinologyOriginal ResearchIncreased Circulation and Adipose Tissue Levels of DNAJC27/<font color="red">RBJ</font> in <font color="#b49700">Obesity</font> and Type 2-DiabetesCherianPreethi T.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC6090877#opentargets-ce16918b739ca3d0259cd9f23551f18e"> <font color="red">ERK</font> is one of the components of the MAPK pathway, which is involved in different biological processes such as cell proliferation and differentiation, metabolism, response to stress, and <font color="#b49700">inflammation</font> (28).</a></p><p style = "font-size:20px">PMC6097452</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/30115078#opentargets-531b3ecd195b65342373d974594505de">1186/s13046-018-0861-9ResearchKPNA2 promotes metabolic reprogramming in <font color="#b49700">glioblastomas</font> by regulation of c-<font color="red">myc</font>LiJieli1935787571@163.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC6097452#opentargets-236f944b974d9d2009d110504cf672fc"> We separately transfected a lentiviral vector of KPNA2 shRNA, wild type KPNA2 or their comparative controls into the U87 (harboring wild-type <font color="red">P53</font>) and U251 (harboring mutant <font color="red">P53</font>) <font color="#b49700">glioblastoma</font> cell lines.</a></p><p style = "font-size:20px">PMC6109242</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC6109242#opentargets-882180a2c74ae49968a70b9a42fb606f">ADEM, acute disseminated encephalomyelitis; ANA, antinuclear antibody; AQP4, aquaporin-4; CIS, clinically isolated syndrome; <font color="red">CSF</font>, cerebrospinal fluid; IPMSSG, International Pediatric Multiple Sclerosis Study Group; IPND, International Panel on <font color="#b49700">Neuromyelitis Optica</font> Diagnosis; MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorders; SS-A, Sjögren syndrome A; SS-B, Sjögren syndrome B.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC6109242#opentargets-49f3fc9f4872723b363f59b0a1dae33a">AQP4, aquaporin4; CSF, cerebrospinal fluid; FGF, fibroblast growth factor; G-CSF, granulocyte-colony stimulating factor; GM-CSF, granulocyte monocyte-colony stimulating factor; IFN, interferon; IL, interleukin; IP, IFN-γ inducible protein; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; <font color="red">MOG</font>, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; PDGF-BB, platelet-derived growth factor-BB; RANTES, regulated on activation normal T cell expressed and secreted; Th, T helper cell; TNF, tumour <font color="#b49700">necrosis</font> factor; Treg, regulatory T cells; VEGF, vascular endothelial growth factor.</a></p><p style = "font-size:20px">PMC6024026</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC6024026#opentargets-22ad6d0046189f89979690ac5a363162"> These animals with increased circulating prorenin, with no change in renin, still had a severe <font color="#b49700">hypertension</font> that was attributed to the increased generation of <font color="red">Ang</font> II [12,13].</a></p><p style = "font-size:20px">PMC5959066</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5959066#opentargets-4977dddb424d47e9a01099b351fb6ad1">The mechanism of action of <font color="#b49700">AIH</font> is complex, but it has been well established that multiple convergent intracellular pathways are responsible for <font color="#b49700">AIH</font>-induced <font color="red">LTF</font> within spinal neurons (for review, see [1]).</a></p><p style = "font-size:20px">PMC6031345</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC6031345#opentargets-6a44499b0219aae13272d5a77470c72f">Antagonists decrease while agonists induce <font color="#b49700">melanoma</font> cell invasion in human epidermal skin reconstructs; agonists switch radial growth phase SBCL2 <font color="#b49700">melanoma</font> cells to an invasive phenotypeTo test the efficacy of the morphogens to alter invasive <font color="#b49700">melanoma</font> growth in a more sophisticated environment, pre-treated <font color="red">BLM</font> <font color="#b49700">melanoma</font> cell aggregates were seeded onto human epidermal skin reconstructs.</a></p><p style = "font-size:20px">PMC5908426</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5908426#opentargets-74240b4ced687dfa2dfd39416112901d">”B2M, β-2-microglobulin; CMV, cytomegalovirus; CRP, C-reactive protein; CTCAE, common terminology for adverse events; EBV, Epstein-Barr virus; eGFR, estimated glomerular filtration rate; ESR, erythrocyte sedimentation rate; FDC, follicular dendritic cell; GC, germinal center; IHC, immunohistochemistry; LANA-1, latency-associated nuclear antigen; LDH, lactate dehydrogenase; <font color="red">MCD</font>, multicentric Castleman's disease; POEMS, polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes; TAFRO, thrombocytopenia, anasarca, <font color="#b49700">myelofibrosis</font>, renal dysfunction, and organomegaly; HHV-8, human herpes virus-8; i<font color="red">MCD</font>, idiopathic <font color="red">MCD</font>; CD, Castleman's disease; IL, interleukin; VEGF, vascular endothelial growth factor.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5908426#opentargets-730382c1a56d68534d062ce0aa00da3d">”B2M, β-2-microglobulin; CMV, cytomegalovirus; CRP, C-reactive protein; CTCAE, common terminology for adverse events; EBV, Epstein-Barr virus; eGFR, estimated glomerular filtration rate; ESR, erythrocyte sedimentation rate; <font color="red">FDC</font>, follicular dendritic cell; GC, germinal center; IHC, immunohistochemistry; LANA-1, latency-associated nuclear antigen; LDH, lactate dehydrogenase; MCD, multicentric Castleman's disease; POEMS, polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes; TAFRO, thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly; <font color="#b49700">HHV-8</font>, human herpes virus-8; iMCD, idiopathic MCD; CD, Castleman's disease; IL, interleukin; VEGF, vascular endothelial growth factor.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5908426#opentargets-91415da8c1c523f573095ab52965436d">”B2M, β-2-microglobulin; CMV, cytomegalovirus; CRP, C-reactive protein; CTCAE, common terminology for adverse events; EBV, Epstein-Barr virus; eGFR, estimated glomerular filtration rate; <font color="red">ESR</font>, erythrocyte sedimentation rate; FDC, follicular dendritic cell; GC, germinal center; IHC, immunohistochemistry; LANA-1, latency-associated nuclear antigen; LDH, lactate dehydrogenase; MCD, multicentric Castleman's disease; POEMS, polyneuropathy, organomegaly, <font color="#b49700">endocrinopathy</font>, M-protein, and skin changes; TAFRO, thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly; HHV-8, human herpes virus-8; iMCD, idiopathic MCD; CD, Castleman's disease; IL, interleukin; VEGF, vascular endothelial growth factor.</a></p><p style = "font-size:20px">PMC5917746</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5917746#opentargets-42975aa5870d845143885a8b567bf0ee">Why does defective <font color="red">ATM</font> signalling caused by C9orf72 expansions not predispose to <font color="#b49700">cancer</font> or immunodeficiency?One of the primary features of ataxia telangiectasia is <font color="#b49700">cancer</font> predisposition, namely lymphomas (Taylor et al.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5917746#opentargets-bd8f874da394c5d4a48520081fc684a2">
Figure 3
The familial ALS protein <font color="red">VCP</font> promotes DNA repair. (A) A schematic depicting the structure of <font color="red">VCP</font> protein highlighting ALS, FTD, and <font color="#b49700">IBMPFD</font> missense mutations.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5917746#opentargets-802f3e29a1d568247a2f4fae0849bf47">
Figure 4
The familial <font color="#b49700">ALS</font> protein <font color="red">FUS</font> promotes DNA repair.</a></p><p style = "font-size:20px">PMC5859435</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/29558905#opentargets-9bf1c8546427acee57ff4fe6bad6af9e">ResultsA risk scoring system was developed with six covariates: etiology, platelet count, Barcelona Clinic <font color="#b49700">Liver Cancer</font> stage, protein induced by vitamin K absence-II, <font color="red">HGF</font>, and FGF.</a></p><p style = "font-size:20px">PMC6048212</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/29531016#opentargets-39bb269576b4e144b1d599e6650c5b71">1042/BSR20170100Research ArticlesResearch Article533947CREB3L1 and <font color="red">PTN</font> expressions correlate with prognosis of <font color="#b49700">brain glioma</font> patientsLiuLi-qiang1FengLi-fei2NanCheng-rui1ZhaoZong-mao11Neurosurgical Department, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China2Neurosurgical Department, Xingtai People’s Hospital, Xingtai, Hebei 054001, ChinaCorrespondence: Zong-mao Zhao (drzmzhao@126.</a></p><p style = "font-size:20px">PMC5823662</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/29507666#opentargets-2b002b685fedaebd62f766ead2bdb4e6"> Interrupting GSTP1 gene expression promoted <font color="#b49700">liver cancer</font> cell proliferation and increased the percentage of cells in S phase by decreasing levels of <font color="red">p21</font> and p27 and increasing p-Akt.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/29507666#opentargets-ea34e75aa2faba17ae3e5edd2ae715a2"> We assessed <font color="red">GST</font> pi 1 (<font color="red">GST</font>P1) mRNA and protein levels in hepatocellular carcinoma (<font color="#b49700">HCC</font>) using genome databases and tissue microarray (TMA) technology.</a></p><p style = "font-size:20px">PMC5800936</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/29484144#opentargets-b6347f2893b53306e7afaeee8e53b215"> PD-L1 expression level was not significantly different between triple (EGFR/<font color="red">ALK</font>/KRAS) wild type <font color="#b49700">NSCLCs</font> and those with EGFR/<font color="red">ALK</font>/KRAS mutation.</a></p><p style = "font-size:20px">PMC5814171</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5814171#opentargets-09d30f00dd03acc7bf19578c3bdda7dc"> In the AOM/DSS model, the PLCγ1, <font color="red">Bak</font>, and cleaved PARP levels were significantly increased in <font color="#b49700">tumors</font> isolated from WT mice, whereas cleaved caspase-3 levels were decreased; however, in PLCγ1 conditional knockout mice, phospho-AKT, phospho-STAT3, and phospho-p65 were all decreased (Figure 2).</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5814171#opentargets-63800b57b6bd68b554dca672e159cbea"> As one of 13 mammalian <font color="red">PLC</font> isozymes, <font color="red">PLC</font> gamma 1 (<font color="red">PLC</font>γ1) is primarily activated by extracellular stimuli and is involved in tyrosine kinase signaling and the promotion of <font color="#b49700">tumor</font> cell growth and migration [11, 12].</a></p><p style = "font-size:20px">PMC5790462</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/29423045#opentargets-3e3dd0b52f40cec931358c276c1495b2">23231Research PaperOvatodiolide targets <font color="#b49700">chronic myeloid leukemia</font> stem cells by epigenetically upregulating hsa-miR-155, suppressing the BCR-<font color="red">ABL</font> fusion gene and dysregulating the PI3K/AKT/mTOR pathwayTuYue-Xing12WangShi-Bing34FuLuo-Qin34LiShuang-Shuang34GuoQian-Peng34WuYi5MouXiao-Zhou34TongXiang-Min3451 Department of Critical Care Medicine, Chun’an First People’s Hospital (Zhejiang Provincial People’s Hospital Chun’an Branch), Hangzhou 311700, Zhejiang Province, China2 Department of Critical Care Medicine, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China3 Clinical Research Institute, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China4 Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Hangzhou 310014, Zhejiang Province, China5 Department of Hematology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, ChinaCorrespondence to: Xiang-Min Tong,tongxiangmin@hmc.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/29423045#opentargets-c6667ead762fb5f5d9cf9835c8b501bc"> Furthermore, we showed that Ova alone or by enhancing the therapeutic potential of Imatinib, reduced the viability of <font color="#b49700">CML</font> cell lines, dose-dependently, irrespective of the cancer stemness, as well as markedly inhibit the <font color="red">Bcr</font>-Abl, p-CrkL, Stat5, and MDR protein expression levels in CD34+ cells.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/29423045#opentargets-f6d2a7ad16da0e79a51d9bd90c46f59d">23231Research PaperOvatodiolide targets <font color="#b49700">chronic myeloid leukemia</font> stem cells by epigenetically upregulating hsa-miR-155, suppressing the <font color="red">BCR</font>-ABL fusion gene and dysregulating the PI3K/AKT/mTOR pathwayTuYue-Xing12WangShi-Bing34FuLuo-Qin34LiShuang-Shuang34GuoQian-Peng34WuYi5MouXiao-Zhou34TongXiang-Min3451 Department of Critical Care Medicine, Chun’an First People’s Hospital (Zhejiang Provincial People’s Hospital Chun’an Branch), Hangzhou 311700, Zhejiang Province, China2 Department of Critical Care Medicine, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China3 Clinical Research Institute, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China4 Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Hangzhou 310014, Zhejiang Province, China5 Department of Hematology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, ChinaCorrespondence to: Xiang-Min Tong,tongxiangmin@hmc.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/29423045#opentargets-2e9a645af14e4639aaaf4440cc5fb965">Chronic myeloid leukemia (<font color="#b49700">CML</font>) is a myeloproliferative pathology, originating from the hematopoietic cancer stem cells (hCSCs) due to the Bcl-<font color="red">Abl</font> Philadelphia chromosome transformation.</a></p><p style = "font-size:20px">PMC5744069</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5744069#opentargets-573d0d8a60011ddbcfe852d4a9beacbc">17, 24, 25, 26, 27, 28, 29Recently, we have demonstrated that Bdnf gene transfer to the arcuate/ventromedial nuclei (<font color="red">ARC</font>/VMH) of the hypothalamus by adeno-associated virus (AAV) robustly reduces adiposity, improves glycemic control, alleviates metabolic syndromes, and decreases central inflammation while not affecting circadian activity and heart or bone function in diet-induced <font color="#b49700">obesity</font> (DIO) mice.</a></p><p style = "font-size:20px">PMC5777820</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5777820#opentargets-9d068b3e0c3aef8fada34e1e824650ed"> Indeed, overexpression of <font color="red">OGT</font> in hepatocytes was sufficient to induce abnormal STIM1 puncta formation and impaired activation of SOCE while down-regulation of <font color="red">OGT</font> in primary hepatocytes from <font color="#b49700">obese</font> mice partially rescued the STIM1 translocation defect.</a></p><p style = "font-size:20px">PMC5714125</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5714125#opentargets-ef328abeb5d6430102cc3e540f087bf2">02Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CRP, C-reactive protein; CT, computed tomography; DM, diabetes mellitus; HCV, hepatitis C virus; HDL-c, high-density lipoprotein cholesterol; HIV, human immunodeficiency virus; hsIL-6, high-sensitivity interleukin-6; HTN, <font color="#b49700">hypertension</font>; LDL-c, low-density lipoprotein cholesterol; Lp-PLA2, lipoprotein-associated phospholipase A2; MCP-1, monocyte chemoattractant protein-1; NNRTIs, Non-nucleoside reverse transcriptase inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; PCSK9, proprotein convertase subtilisin/kexin 9; PIs, protease inhibitors; sCD14, soluble CD14; sCD163, soluble CD163; VL, viral load; WHR, waist-to-<font color="red">hip</font> ratio.</a></p><p style = "font-size:20px">PMC5709988</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5709988#opentargets-72303e275f37f716cee282d70e216c41"> No significant differences in adiponectin protein concentrations were observed between the “healthy” obese subjects and these with obesity-related <font color="#b49700">complications</font>.Fig. 2The mean ADIPOQ mRNA levels (a) and mean adiponectin protein concentrations (b) in the visceral (VAT) and subcutaneous (<font color="red">SAT</font>) adipose tissues of obese (O) and normal-weight (N) individuals.</a></p><p style = "font-size:20px">PMC5711892</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5711892#opentargets-9840bc3e98e62d468de408311a06d595"> The <font color="red">Shh</font>-positive area was slightly reduced in diabetic kidney at 5 weeks because of the replacement of <font color="#b49700">inflammation</font> and expansion of the extracellular matrix.</a></p><p style = "font-size:20px">PMC5699111</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/29162134#opentargets-49fdbab58b4f8a7632896081beaaa60e"> We examined the drug-induced change in serum <font color="red">TK1</font> as well as its correlation with change in <font color="#b49700">tumor</font> Ki-67 levels in patients enrolled in the NeoPalAna trial (ClinicalTrials.</a></p><p style = "font-size:20px">PMC5815529</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5815529#opentargets-676f54352a8570be9dae45fe09a50ea3">
Abbreviations: CDK = cyclin-dependent kinase; EGFR = endothelial growth factor receptor; NF-κB = nuclear factor-κB; HIF-1α = hypoxia-inducible factor 1α; VEGF = vascular endothelial growth factor; <font color="red">MVD</font> = microvessel density; VASH1 = vasohibin-1; TSP-1 = thrombospondin-1; FGFR3 = fibroblast growth factor receptor 3; <font color="#b49700">MMPs</font> = metalloproteinases; Bcl-2 = B-cell lymphoma 2 oncogene.</a></p><p style = "font-size:20px">PMC5641600</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/29031717#opentargets-34939d7c49f55ce305e4438373fe247b">MethodsGcgr siRNA encapsulated into LNPs or leptin was administered to mice with <font color="#b49700">diabetes</font> due to injection of the β-cell toxin streptozotocin (<font color="red">STZ</font>) alone or combined with high fat diet (HFD/<font color="red">STZ</font>).</a></p><p style = "font-size:20px">PMC5612928</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/28947822#opentargets-166bd56e632476d8e8a0e7486a0ad947">1038/s41598-017-12135-7ArticleMicroenvironment regulates the expression of miR-21 and <font color="#b49700">tumor</font> suppressor genes PTEN, PIAS3 and PDCD4 through <font color="red">ZAP</font>-70 in chronic lymphocytic leukemiaCarabiaJúliaCarpioCeciliaAbrisquetaPauJiménezIsabelPurroyNoeliaCalpeEvaPalacioCarlesBoschFrancescfbosch@vhio.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5612928#opentargets-5ffb21522b3357c5d10a62cfd20bb2c3"> Indeed, <font color="#b49700">CLL</font> cells are highly dependent on interactions with the microenvironment, as evidenced by the spontaneous apoptosis occurring ex vivo and the clinical relevance of impeding the access of <font color="#b49700">CLL</font> cells to lymph nodes and bone marrow that targeted treatments such as <font color="red">BTK</font> or PI3K inhibitors induce2.</a></p><p style = "font-size:20px">PMC5581426</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5581426#opentargets-cf5056a9479cf5b3576f2922aa460a3b"> White matter of lumbar spinal cord sections from non-<font color="#b49700">EAE</font> control (<font color="red">CTR</font>), untreated <font color="#b49700">EAE</font> mouse (<font color="#b49700">EAE</font>), and <font color="#b49700">EAE</font> mouse treated with glibenclamide starting on pid-24 (<font color="#b49700">EAE</font> + G), stained with Luxol fast blue (LFB) (myelin) or immunolabeled for myelin basic protein (MBP) (myelin), CNPase (mature oligodendrocytes), PDGFR-α (oligodendrocyte progenitor cells; OPC) or SMI-312 (neurofilament marker), as indicated; nuclei stained with DAPI in the MBP sections; original magnification, × 200 (LFB) or × 400 (all immunolabelings); bar graphs: percent of quadrants with myelin loss by LFB staining, MBP immunolabeling, or CNPase immunolabeling; quantification of PDGFR-α-expressing OPC near the central canal; percent of quadrants with axonal loss by SMI-132 labeling; 5 mice/group; ##
P < 0.</a></p><p style = "font-size:20px">PMC5448529</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5448529#opentargets-078b8b776ae86e27a9dd5508d1ee9bb1"> Note that a subset of genes in the <font color="#b49700">hypoxia</font> + E2 group demonstrated an expression pattern similar to that in normoxia controls (black box), whereas no such pattern was noted in <font color="#b49700">hypoxia</font> controls or hypoxic animals treated with E2 and ER antagonist ICI 182,780. Nkd2, naked cuticle homolog 2 (Drosophila); Thbs2, thrombospondin 2; Cpxm2, carboxypeptidase X (M14 family), member 2; Olfml2b, olfactomedin-like 2B; Lypd1, <font color="red">Ly6</font>/Plaur domain containing 1; Uck2, uridine-cytidine kinase 2; Mustn1, musculoskeletal, embryonic nuclear protein 1; Inhba, inhibin beta-A; Rab4a, RAB4A, member RAS oncogene family; Fbln7, fibulin 7; Grem1, gremlin 1; Ccl21, chemokine (C-C motif) ligand 21; Fblim1, filamin binding LIM protein 1; Dpys15, dihydropyrimidinase-like 5; Robo4, roundabout homolog 4.</a></p><p style = "font-size:20px">PMC5442131</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5442131#opentargets-6d1e3706c73be3350728ebdbd6a5108b"> To verify whether <font color="#b49700">LCM</font> actually activated TLR4, a TLR4 reporter cell-line, <font color="red">HEK</font>293 cells that overexpress TLR4 (<font color="red">HEK</font>-Blue hTLR4, InvivoGen), was treated with <font color="#b49700">LCM</font> and resulted in activation of TLR4-controlled reporter gene, secreted embryonic alkaline phosphatase (SEAP, Fig.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5442131#opentargets-4633ebcda51fca7517f19529cc3c744a"> <font color="#b49700">Cancer</font>-induced muscle catabolism involves activation of proteolysis mediated by the ubiquitin-proteasome pathway (<font color="red">UPP</font>)5 in muscle cells through cytokine-activated signaling molecules including NF-κB6, 7, p38 MAPK8–10 or JAK-STAT3 pathways9, 11.</a></p><p style = "font-size:20px">PMC5428978</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5428978#opentargets-db2fa5cc8a12b953a973b915d4e70dd7">(A) ALDHhiCD44+CD24- and ALDHloCD44-CD24+ cell subpopulations were isolated from the MDA-MB-231 human <font color="#b49700">breast cancer</font> cell line by FACS and subjected to transwell migration assays (5 x 104 cells/well; 8μm pore size) using basal media (DMEM/<font color="red">F12</font> + Mito+), BMCM, or BMCM depleted of OPN (ΔOPN).</a></p><p style = "font-size:20px">PMC5670028</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/28465529#opentargets-de6f6cdc7c2a91f368e3585bbe370da1">13328465529Original ArticleWnt5a induces ROR1 to complex with <font color="red">HS1</font> to enhance migration of <font color="#b49700">chronic lymphocytic leukemia</font> cellsWnt5a induces ROR1 to complex with <font color="red">HS1</font>HasanM K1YuJ1ChenL1CuiBing1Widhopf IIG F1RassentiL1ShenZ2BriggsS P2KippsT J1*1Moores Cancer Center, University of California San Diego, La Jolla, CA, USA2Section of Cell and Developmental Biology, University of California San Diego, La Jolla, CA, USA*Medicine, University of California San Diego, 3855 Health Sciences Drive #0820, La Jolla, CA, USA.</a></p><p style = "font-size:20px">PMC5421935</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/28445981#opentargets-cd0404d229349ecccd7985734bd42c90"> In vitro experiments showed that GADD45A negatively regulates IDH1R132H glioma cell proliferation, migration, and invasion, and neurosphere formation in IDH1R132H <font color="#b49700">glioblastoma</font> stem cells (<font color="red">GSC</font>).</a></p><p style = "font-size:20px">PMC5385467</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/28443245#opentargets-ef5e80789732e527711c7f26f2fee81f"> Consistently, a high expression of <font color="red">IF1</font> in hepatocarcinomas and in <font color="#b49700">carcinomas of the lung</font>, bladder, and stomach and in gliomas is a biomarker of bad patient prognosis.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5385467#opentargets-14fcda75c715262041092cd41d08e069"> However, we show that the overexpression of IF1 in <font color="#b49700">breast cancer</font> cells has no significant impact in cellular growth and cell death response to <font color="red">STS</font> and hydrogen peroxide.</a></p><p style = "font-size:20px">PMC5471010</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/28410235#opentargets-9870553aa9ef92719ad57a95034665f3"> Furthermore, Cysltr1−/− mice exhibited an overall reduction in inflammation, with a significant decrease in proinflammatory cytokines, <font color="#b49700">polyp</font> 5-<font color="red">LOX</font> expression and infiltration of CD45 leukocytes and F4/80 macrophages.</a></p><p style = "font-size:20px">PMC5326762</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5326762#opentargets-bb0dbf985b6a498ba7d5bf55a9340bb8">, 2006ERG, electroretinography; Bcl-XL, <font color="#b49700">B-cell lymphoma</font>-extra large; p, phosphorylation; BAD, Bcl2-associated agonist of cell death; Bax, BCL2-associated x protein; ERK, extracellular signal-regulated kinase; Akt, Akt serine/threonine kinase; STAT, signal transducer and activator of transcription; JAK2, Janus kinase 2; PI3K, phosphoinositide 3-kinase; MAPK or MEK, mitogen-activated protein kinase; p75NTR-pro-NT3, p75 neurotrophin receptor-pro-mature neurotrophin-3; c-<font color="red">fos</font>, <font color="red">fos</font> proto-oncogene; bcl-2, <font color="#b49700">B-cell lymphoma</font>-2; c-FLIP, cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein; IRS1, insulin receptor substrate 1; NF-κB, nuclear factor-κB; DI-E-RAMP2(−/−), drug-inducible vascular endothelial cell-specific RAMP2 knockout (−/−) mice; RAMP2, receptor activity modifying protein 2; RBC, red blood cells; WT, wildtype; KO, knockout; iNOS, inducible nitric oxide synthase; eNOS, endothelial nitric oxide synthase; nNOS, neuronal nitric oxide synthase; ↑, promote or increase or induce; ↓, inhibit or decrease or suppress.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5326762#opentargets-b7e8cdd39404e08a52184fb7283d0d47">, 2006ERG, electroretinography; Bcl-XL, <font color="#b49700">B-cell lymphoma</font>-extra large; p, phosphorylation; BAD, Bcl2-associated agonist of cell death; Bax, BCL2-associated x protein; ERK, extracellular signal-regulated kinase; Akt, Akt serine/threonine kinase; STAT, signal transducer and activator of transcription; JAK2, Janus kinase 2; PI3K, phosphoinositide 3-kinase; MAPK or MEK, mitogen-activated protein kinase; p75NTR-pro-<font color="red">NT3</font>, p75 neurotrophin receptor-pro-mature neurotrophin-3; c-fos, fos proto-oncogene; bcl-2, <font color="#b49700">B-cell lymphoma</font>-2; c-FLIP, cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein; IRS1, insulin receptor substrate 1; NF-κB, nuclear factor-κB; DI-E-RAMP2(−/−), drug-inducible vascular endothelial cell-specific RAMP2 knockout (−/−) mice; RAMP2, receptor activity modifying protein 2; RBC, red blood cells; WT, wildtype; KO, knockout; iNOS, inducible nitric oxide synthase; eNOS, endothelial nitric oxide synthase; nNOS, neuronal nitric oxide synthase; ↑, promote or increase or induce; ↓, inhibit or decrease or suppress.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5326762#opentargets-81f3717293a2d045dc877c6ef690becb">, 2008ADMCulture under normoxic or hypoxic conditions<font color="red">RPE</font> cellsHypoxia ↑ADM in all three human <font color="red">RPE</font> cell lines, ADM treatment ↓the <font color="#b49700">hypoxia</font>-induced cell number decreaseADM induced by <font color="#b49700">hypoxia</font> protects cell damage in <font color="red">RPE</font> cellsUdono et al.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5326762#opentargets-f914b7bf4756bd48d10c117354363e0b">, 2006ERG, electroretinography; Bcl-XL, <font color="#b49700">B-cell lymphoma</font>-extra large; p, phosphorylation; BAD, Bcl2-associated agonist of cell death; <font color="red">Bax</font>, BCL2-associated x protein; ERK, extracellular signal-regulated kinase; Akt, Akt serine/threonine kinase; STAT, signal transducer and activator of transcription; JAK2, Janus kinase 2; PI3K, phosphoinositide 3-kinase; MAPK or MEK, mitogen-activated protein kinase; p75NTR-pro-NT3, p75 neurotrophin receptor-pro-mature neurotrophin-3; c-fos, fos proto-oncogene; bcl-2, <font color="#b49700">B-cell lymphoma</font>-2; c-FLIP, cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein; IRS1, insulin receptor substrate 1; NF-κB, nuclear factor-κB; DI-E-RAMP2(−/−), drug-inducible vascular endothelial cell-specific RAMP2 knockout (−/−) mice; RAMP2, receptor activity modifying protein 2; RBC, red blood cells; WT, wildtype; KO, knockout; iNOS, inducible nitric oxide synthase; eNOS, endothelial nitric oxide synthase; nNOS, neuronal nitric oxide synthase; ↑, promote or increase or induce; ↓, inhibit or decrease or suppress.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5326762#opentargets-3d05681786525047bf29db26fa4b01d9"> The known <font color="#b49700">hypoxia</font>-inducible factor (HIF) targets such as erythropoietin (EPO), vascular endothelial growth factor (VEGF), heme oxygenase-1 (HO-1), adrenomedullin (<font color="red">ADM</font>), glucose transporter-1 (Glut-1), etc.</a></p><p style = "font-size:20px">PMC5300292</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5300292#opentargets-9530155b5eea2be01dfbac3f951c1b26">The <font color="#b49700">endometrial carcinoma</font> cell line <font color="red">HEC</font>-1-A was incubated in 100% methanol (chilled at −20 °C) at room temperature for 5 min and fixed with 4% paraformaldehyde in PBS at pH 7.</a></p><p style = "font-size:20px">PMC5172551</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/27997540#opentargets-03b065a7c9d155babea406192b82880b">To explore how these mutations in IL7R signaling pathway genes cause steroid resistance and subsequent poor outcome, we expressed wild-type and mutant IL7R signaling molecules in two steroid-sensitive <font color="#b49700">T-ALL</font> cell lines (SUPT1 and <font color="red">P12</font> Ichikawa cells) using inducible lentiviral expression constructs.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5172551#opentargets-cdd73e515b2bbf46f693ca19c7063443">To evaluate the recurrence of 137 high-confidence mutated genes and seven validated low-confidence mutated genes as identified by WGS (S2 Table), we sequenced the diagnostic samples of 69 genetically and clinically well-annotated T-ALL patients by <font color="red">TES</font> for these 144 genes, together with an additional set of 110 genes that are recurrently mutated in <font color="#b49700">leukemia</font> [24,25] (S1 and S3 Tables).</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5172551#opentargets-716681a25fa7d47716830228ee8c26ad">PatientChemotherapyInhibitorCI ± SDSynergy LevelDrugIC50 [nM] (Maximum Effect)CompoundTargetIC50 [nM] (Maximum Effect)ED50ED75<font color="#b49700">T-ALL</font> #9858 (TLX3tr, p16/p15DEL/DEL; mutations in IL7R, NRAS, NOTCH1 [HD domain], <font color="red">WT1</font>, BCL11B, CDH9, STIL)Prednisolone18 (80%)RuxolitinibJAK1205 (<20%)1.</a></p><p style = "font-size:20px">PMC5133736</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/27906058#opentargets-515fb7f98487896d84b02073ac4b42c7"> The aim of this study was to compare VEGF levels in patients over 60 years of age who have RS3PE, RA, PMR or <font color="red">GCA</font> so as to determine whether elevated VEGF is specific for a rheumatic disease, the <font color="#b49700">inflammation</font> or edema that occurs with these pathological conditions.</a></p><p style = "font-size:20px">PMC5045056</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5045056#opentargets-d6bace448846bb5b001bc461c60982cc"> One important area for future study will be comparing the effects of acute versus chronic <font color="#b49700">hypoxia</font> and investigating the role of negative feedback mechanisms such as HIF-mediated induction of PHD and <font color="red">VHL</font> transcription in chronic activation of the HIF/hydroxylase pathway.</a></p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5045056#opentargets-fec618e25233777bbfe2c0c96e061d87"> One important area for future study will be comparing the effects of acute versus chronic <font color="#b49700">hypoxia</font> and investigating the role of negative feedback mechanisms such as HIF-mediated induction of <font color="red">PHD</font> and VHL transcription in chronic activation of the HIF/hydroxylase pathway.</a></p><p style = "font-size:20px">PMC5017763</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/27612200#opentargets-6ab5f490f20eeb4d3454514148f96107">ResultsSignificant differences in circulating OPN, YKL-40 and <font color="red">TNC</font> concentrations between the experimental groups were observed, being significantly increased due to obesity (P<0.01) and <font color="#b49700">colon cancer</font> (P<0.</a></p><p style = "font-size:20px">PMC5095254</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5095254#opentargets-c3afcc05742092bd9782e735a3a464ae"> In group 2 (molecular defined DSD diagnoses other than <font color="#b49700">AIS</font>), there were also no AR-<font color="red">CDS</font> or intron-exon boundary mutations.</a></p><p style = "font-size:20px">PMC5342526</p><p style = "font-size:20px"><a href="http://europepmc.org/articles/PMC5342526#opentargets-56a3d39a41f1b9aeec290799015c3ab5"> Furthermore, Bisindolylmaleimide IX also shows increased cytotoxicity to BCR-ABL positive cells by inhibiting the oncogene <font color="#b49700">addiction</font> <font color="red">Raf</font>-Erk pathway [6, 28].</a></p><p style = "font-size:20px">PMC4999516</p><p style = "font-size:20px"><a href="http://europepmc.org/abstract/MED/27553854#opentargets-92c37dbaf83e233d9ba772624eefb0e0"> We find that LncSox4 is required for liver <font color="red">TIC</font> self-renewal and <font color="#b49700">tumour</font> initiation.</a></p><p style = "font-size:20px">82 examples over 49 pmcids</p>